Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Jacqulyne P. Robichaux, Yasir Y. Elamin, Zhi Tan, Brett W. Carter, Shuxing Zhang, Shengwu Liu, Shuai Li, Ting Chen, Alissa Poteete, Adriana Estrada-Bernal, Anh T. Le, Anna Truini, Monique B. Nilsson, Huiying Sun, Emily Roarty, Sarah B. Goldberg, Julie Brahmer, Mehmet Altan, Charles Lu, Vassiliki Papadimitrakopoulou & 4 others Katerina Politi, Robert C. Doebele, Kwok Kin Wong, John V. Heymach

Research output: Contribution to journalArticle

Abstract

Although most activating mutations of epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancers (NSCLCs) are sensitive to available EGFR tyrosine kinase inhibitors (TKIs), a subset with alterations in exon 20 of EGFR and HER2 are intrinsically resistant and lack an effective therapy. We used in silico, in vitro, and in vivo testing to model structural alterations induced by exon 20 mutations and to identify effective inhibitors. 3D modeling indicated alterations restricted the size of the drug-binding pocket, limiting the binding of large, rigid inhibitors. We found that poziotinib, owing to its small size and flexibility, can circumvent these steric changes and is a potent inhibitor of the most common EGFR and HER2 exon 20 mutants. Poziotinib demonstrated greater activity than approved EGFR TKIs in vitro and in patient-derived xenograft models of EGFR or HER2 exon 20 mutant NSCLC and in genetically engineered mouse models of NSCLC. In a phase 2 trial, the first 11 patients with NSCLC with EGFR exon 20 mutations receiving poziotinib had a confirmed objective response rate of 64%. These data identify poziotinib as a potent, clinically active inhibitor of EGFR and HER2 exon 20 mutations and illuminate the molecular features of TKIs that may circumvent steric changes induced by these mutations.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalNature Medicine
DOIs
StateAccepted/In press - Apr 23 2018

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Exons
Phosphotransferases
Cells
Mutation
Protein-Tyrosine Kinases
Structural Models
Heterografts
Computer Simulation
HM781-36B
Testing
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Robichaux, J. P., Elamin, Y. Y., Tan, Z., Carter, B. W., Zhang, S., Liu, S., ... Heymach, J. V. (Accepted/In press). Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer. Nature Medicine, 1-9. https://doi.org/10.1038/s41591-018-0007-9

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer. / Robichaux, Jacqulyne P.; Elamin, Yasir Y.; Tan, Zhi; Carter, Brett W.; Zhang, Shuxing; Liu, Shengwu; Li, Shuai; Chen, Ting; Poteete, Alissa; Estrada-Bernal, Adriana; Le, Anh T.; Truini, Anna; Nilsson, Monique B.; Sun, Huiying; Roarty, Emily; Goldberg, Sarah B.; Brahmer, Julie; Altan, Mehmet; Lu, Charles; Papadimitrakopoulou, Vassiliki; Politi, Katerina; Doebele, Robert C.; Wong, Kwok Kin; Heymach, John V.

In: Nature Medicine, 23.04.2018, p. 1-9.

Research output: Contribution to journalArticle

Robichaux, JP, Elamin, YY, Tan, Z, Carter, BW, Zhang, S, Liu, S, Li, S, Chen, T, Poteete, A, Estrada-Bernal, A, Le, AT, Truini, A, Nilsson, MB, Sun, H, Roarty, E, Goldberg, SB, Brahmer, J, Altan, M, Lu, C, Papadimitrakopoulou, V, Politi, K, Doebele, RC, Wong, KK & Heymach, JV 2018, 'Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer', Nature Medicine, pp. 1-9. https://doi.org/10.1038/s41591-018-0007-9
Robichaux, Jacqulyne P. ; Elamin, Yasir Y. ; Tan, Zhi ; Carter, Brett W. ; Zhang, Shuxing ; Liu, Shengwu ; Li, Shuai ; Chen, Ting ; Poteete, Alissa ; Estrada-Bernal, Adriana ; Le, Anh T. ; Truini, Anna ; Nilsson, Monique B. ; Sun, Huiying ; Roarty, Emily ; Goldberg, Sarah B. ; Brahmer, Julie ; Altan, Mehmet ; Lu, Charles ; Papadimitrakopoulou, Vassiliki ; Politi, Katerina ; Doebele, Robert C. ; Wong, Kwok Kin ; Heymach, John V. / Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer. In: Nature Medicine. 2018 ; pp. 1-9.
@article{5ad6fb291d26453cb4e9d8fd750d573a,
title = "Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer",
abstract = "Although most activating mutations of epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancers (NSCLCs) are sensitive to available EGFR tyrosine kinase inhibitors (TKIs), a subset with alterations in exon 20 of EGFR and HER2 are intrinsically resistant and lack an effective therapy. We used in silico, in vitro, and in vivo testing to model structural alterations induced by exon 20 mutations and to identify effective inhibitors. 3D modeling indicated alterations restricted the size of the drug-binding pocket, limiting the binding of large, rigid inhibitors. We found that poziotinib, owing to its small size and flexibility, can circumvent these steric changes and is a potent inhibitor of the most common EGFR and HER2 exon 20 mutants. Poziotinib demonstrated greater activity than approved EGFR TKIs in vitro and in patient-derived xenograft models of EGFR or HER2 exon 20 mutant NSCLC and in genetically engineered mouse models of NSCLC. In a phase 2 trial, the first 11 patients with NSCLC with EGFR exon 20 mutations receiving poziotinib had a confirmed objective response rate of 64{\%}. These data identify poziotinib as a potent, clinically active inhibitor of EGFR and HER2 exon 20 mutations and illuminate the molecular features of TKIs that may circumvent steric changes induced by these mutations.",
author = "Robichaux, {Jacqulyne P.} and Elamin, {Yasir Y.} and Zhi Tan and Carter, {Brett W.} and Shuxing Zhang and Shengwu Liu and Shuai Li and Ting Chen and Alissa Poteete and Adriana Estrada-Bernal and Le, {Anh T.} and Anna Truini and Nilsson, {Monique B.} and Huiying Sun and Emily Roarty and Goldberg, {Sarah B.} and Julie Brahmer and Mehmet Altan and Charles Lu and Vassiliki Papadimitrakopoulou and Katerina Politi and Doebele, {Robert C.} and Wong, {Kwok Kin} and Heymach, {John V.}",
year = "2018",
month = "4",
day = "23",
doi = "10.1038/s41591-018-0007-9",
language = "English (US)",
pages = "1--9",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

AU - Robichaux, Jacqulyne P.

AU - Elamin, Yasir Y.

AU - Tan, Zhi

AU - Carter, Brett W.

AU - Zhang, Shuxing

AU - Liu, Shengwu

AU - Li, Shuai

AU - Chen, Ting

AU - Poteete, Alissa

AU - Estrada-Bernal, Adriana

AU - Le, Anh T.

AU - Truini, Anna

AU - Nilsson, Monique B.

AU - Sun, Huiying

AU - Roarty, Emily

AU - Goldberg, Sarah B.

AU - Brahmer, Julie

AU - Altan, Mehmet

AU - Lu, Charles

AU - Papadimitrakopoulou, Vassiliki

AU - Politi, Katerina

AU - Doebele, Robert C.

AU - Wong, Kwok Kin

AU - Heymach, John V.

PY - 2018/4/23

Y1 - 2018/4/23

N2 - Although most activating mutations of epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancers (NSCLCs) are sensitive to available EGFR tyrosine kinase inhibitors (TKIs), a subset with alterations in exon 20 of EGFR and HER2 are intrinsically resistant and lack an effective therapy. We used in silico, in vitro, and in vivo testing to model structural alterations induced by exon 20 mutations and to identify effective inhibitors. 3D modeling indicated alterations restricted the size of the drug-binding pocket, limiting the binding of large, rigid inhibitors. We found that poziotinib, owing to its small size and flexibility, can circumvent these steric changes and is a potent inhibitor of the most common EGFR and HER2 exon 20 mutants. Poziotinib demonstrated greater activity than approved EGFR TKIs in vitro and in patient-derived xenograft models of EGFR or HER2 exon 20 mutant NSCLC and in genetically engineered mouse models of NSCLC. In a phase 2 trial, the first 11 patients with NSCLC with EGFR exon 20 mutations receiving poziotinib had a confirmed objective response rate of 64%. These data identify poziotinib as a potent, clinically active inhibitor of EGFR and HER2 exon 20 mutations and illuminate the molecular features of TKIs that may circumvent steric changes induced by these mutations.

AB - Although most activating mutations of epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancers (NSCLCs) are sensitive to available EGFR tyrosine kinase inhibitors (TKIs), a subset with alterations in exon 20 of EGFR and HER2 are intrinsically resistant and lack an effective therapy. We used in silico, in vitro, and in vivo testing to model structural alterations induced by exon 20 mutations and to identify effective inhibitors. 3D modeling indicated alterations restricted the size of the drug-binding pocket, limiting the binding of large, rigid inhibitors. We found that poziotinib, owing to its small size and flexibility, can circumvent these steric changes and is a potent inhibitor of the most common EGFR and HER2 exon 20 mutants. Poziotinib demonstrated greater activity than approved EGFR TKIs in vitro and in patient-derived xenograft models of EGFR or HER2 exon 20 mutant NSCLC and in genetically engineered mouse models of NSCLC. In a phase 2 trial, the first 11 patients with NSCLC with EGFR exon 20 mutations receiving poziotinib had a confirmed objective response rate of 64%. These data identify poziotinib as a potent, clinically active inhibitor of EGFR and HER2 exon 20 mutations and illuminate the molecular features of TKIs that may circumvent steric changes induced by these mutations.

UR - http://www.scopus.com/inward/record.url?scp=85045836012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045836012&partnerID=8YFLogxK

U2 - 10.1038/s41591-018-0007-9

DO - 10.1038/s41591-018-0007-9

M3 - Article

SP - 1

EP - 9

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

ER -